Columnist Kylene Henderson is starting the year by focusing on progress and wellness, even if it means only small changes.

New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary ...

Columnist Ann Reynoso may have looked well during a recent holiday gathering, but living with PF meant she was battling ...

Columnist Sam Kirton explores what options are available to help IPF patients meet the costs of their medical care and medications.

The gut bacteria B. adolescentis eased lung scarring in a pulmonary fibrosis mouse model, showing potential as a preventive ...

Time felt like it was moving in slow motion for columnist Samuel Kirton after his IPF diagnosis. A lung transplant changed everything.

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...

[vc_row][vc_column][vc_column_text]Pulmonary fibrosis (PF) is a respiratory disease that causes the lung tissue to become thick and stiff. Over time, it turns into scar tissue, which is known as ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...